OmniUltra™: Interact with Targets Differently
OmniUltra is a versatile in vivo discovery platform that generates naturally optimized human immune antibody repertoires featuring cow-inspired ultralong CDRH3 domains. With a dramatically different paratope shape than those of traditional antibodies or antibody fragments, OmniUltra antibodies can interact with established therapeutic targets in new ways and potentially unlock other targets thought to be undruggable by conventional antibodies.
Not Your Average Chickens
The OmniUltra platform leverages uniquely engineered chickens that integrate key features of human, cow, and avian immune systems to generate novel repertoires with ultralong CDRH3 regions for drug discovery. By combining the evolutionary distance advantage of a chicken host with novel paratope structures, OmniUltra antibodies may provide expanded epitope coverage of human proteins, delivering differentiated antibody repertoires with exceptional optionality and versatility for next-generation therapeutics.
The Ultralong Advantage
Uniquely access a wide array of targets
OmniUltra CDRH3 regions are three times longer than an average human CDRH3 and form a stalk-knob structure that protrudes outward from human framework regions. While other CDR regions of the VH and VL may contribute to target binding, the knob sequence is heavily diversified during affinity maturation and is the dominant binding element in the majority of OmniUltra antibodies. This allows for different types of antibody-antigen interactions as compared to conventional antibodies, and in some cases may unlock novel target biology.
Stalk-knob “portability” to other biologics for multispecifics and CAR-T therapy
Bispecific and multispecific antibody therapeutics: With a diverse array of conjugation possibilities, the OmniUltra platform enables the versatile construction of bi- and multispecific antibodies for enhanced therapeutic impact.
CAR-T therapy: OmniUltra peptides provide flexible binding units for CAR-T constructs or targeted delivery molecules, enabling precise recognition and destruction of cancer cells.
In vivo optimized
Generate diverse, target-specific repertoires, powered by natural immune systems to capture the characteristics and binding profiles that work.
Repertoires are enriched for pre-optimized sequences
Generate unique human antibodies with built-in specificity, affinity, and stability, accelerating hit-to-lead identification.
Questions about OmniUltra? Connect with OmniAb today.
At OmniAb, we’re proud of our reputation on the forefront of transgenic research. To discover how the OmniUltra platform can fit into your laboratory’s workflow, get in touch with us today.